Key data from Merck’s pipeline to be presented at ASCO:
- First presentation of results from Cohort 1 of a Phase 1/2 study evaluating the anti-LAG-3 antibody, favezelimab plus KEYTRUDA in patients with anti-PD-1-naïve relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) (Abstract #7516). Results for Cohort 2 of this study evaluating favezelimab plus KEYTRUDA in patients with R/R cHL after anti-PD-1 treatment will also be presented for the first time (Abstract #7545).
Ann: Immutep to announce new TACTI-002 data at ASCO 2022, page-32
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.010(3.08%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.0¢ | $584.2K | 1.787M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 311433 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 113721 | 6 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |